Wan X, et al. - From the US payer perspective, atezolizumab for metastatic non–small cell lung cancer (NSCLC) was tested with respect to its cost-effectiveness in the first-line treatment setting. Researchers created a Markov model and compared the combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) with the combination of bevacizumab, carboplatin, and paclitaxel (BCP) and carboplatin and paclitaxel (CP), in terms of lifetime cost and efficacy, in the first-line treatment. Compared with BCP and CP, an additional 0.413 quality-adjusted life-years [QALYs] and 0.738 QALYs were offered by ABCP, respectively; with corresponding incremental costs of $234,998 and $381,116, respectively. At a willingness-to-pay threshold of $100,000 per QALY, no cost-effectiveness of ABCP vs BCP or CP was found, from the perspective of the US payer, when administered in the first-line setting for patients with metastatic, nonsquamous NSCLC.